



**March 2024**

**IMPORTANT CLARIFICATION REGARDING TEGSEDI IN LATAM**

PTC Therapeutics has exclusive rights from Akcea Therapeutics Inc, a subsidiary of Ionis Pharmaceuticals, Inc., to commercialize Tegsedi (inotersen) in Latin America and certain Caribbean countries. PTC has been treating hATTR patients in Latin America for over 5 years and remains committed to the hereditary amyloidosis community in this region and the continued supply for Tegsedi (inotersen) to patients in the region.